Get notified when VBIO files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: VBIO Valion Bio, Inc. 8-K

Valion Bio reports Q1 2026 financial results in routine earnings disclosure

Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read

Key Changes

  • medium

    Company issued press release announcing financial results for quarter ended March 31, 2026. Specific figures are in the attached exhibit, not disclosed in the 8-K body.

    Item 2.02 verify on EDGAR →
  • low

    Filing references Exhibit 99.1 press release dated May 14, 2026, but the 8-K text appears incomplete with truncated Item 2.02 disclosure.

    8-K: Exhibits verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.

Partner

Trade VBIO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify